Diffuse Large B-Cell Lymphoma News

News

FDA Grants Approval to Epcoritamab for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Grade Lymphoma

05/22/2023

Jordan Kadish

On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp for the treatment of relapsed/refractory DLBCL not otherwise specified, including DLBCL from indolent lymphoma and high-grade B-cell lymphoma.

On May 19, 2023, the FDA granted...

05/22/2023

Oncology

News

05/12/2023

Jordan Kadish

According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.

According to findings from a...

05/12/2023

Oncology

News

Potential Benefit of Bortezomib Plus R-CHOP Treatment for Patients With Activated B-Cell and Molecular High-Grade Subtype DLBCL

05/05/2023

Jordan Kadish

Findings from the phase 3 REMoDL-B trial indicate that patients with activated B-cell and molecular high-grade subtype diffuse large B-cell lymphoma may benefit from the addition of bortezomib to R-CHOP in initial therapy.

Findings from the phase 3...

05/05/2023

Oncology

News

FDA Grants Approval to Polatuzumab Vedotin for Patients With Previously Untreated DLBCL and High-Grade B-Cell Lymphoma

04/21/2023

Jordan Kadish

The FDA granted approval to polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) treatment for adult patients with previously untreated DLBCL, not otherwise specified, or high-grade B-cell...

The FDA granted approval to...

04/21/2023

Oncology

News

Subcutaneous Epcoritamab Combined With R-Dhax/C Yielded High ORR and CMR Rates in Patients With R/R DLBCL

02/10/2023

Jordan Kadish

An updated phase 1/2 dose escalation study found that a combination of subcutaneous epcoritamab and R-Dhax/C luxeptinib for patients with R/R diffuse b-cell lymphoma resulted in high ORR and CMR rates.

An updated phase 1/2 dose...

02/10/2023

Oncology

News

Bendamustine Demonstrates Safety, Efficacy for Lymphodepletion Before Tisagenlecleucel in R/R Large B-Cell Lymphoma

09/30/2022

Gina Tomaine

Bendamustine is an effective lymphodepletion regimen before tisagenlecleucel in patients with refractory/relapsed large B-cell lymphomas, according to a recent study.

Bendamustine is an effective...

09/30/2022

Oncology

News

PILOT Trial Supports Lisocabtagene Maraleucel as Second-Line Therapy for Relapsed/Refractory LBCL

09/02/2022

Gina Tomaine

Lisocabtagene maraleucel demonstrates promising safety and efficacy as a second-line treatment for patients with LBCL not eligible for hematopoietic stem-cell transplantation, according to findings from the PILOT trial.

Lisocabtagene maraleucel...

09/02/2022

Oncology

News

Targeted Therapy Combinations Feasible Before Chemoimmunotherapy for Newly Diagnosed DLBCL: Smart Start Trial

09/02/2022

Gina Tomaine

Rituximab plus lenalidomide and ibrutinib demonstrated significant clinical activity, manageable safety, and promising survival outcomes both alone and in combination with chemotherapy as a frontline treatment for newly diagnosed DLBCL in the...

Rituximab plus lenalidomide and...

09/02/2022

Oncology

News

Second-Line Lisocabtagene Maraleucel vs Standard of Care for Relapsed/Refractory LBCL: TRANSFORM Trial

08/23/2022

Gina Tomaine

An interim analysis of the phase 3 TRANSFORM trial has shown significantly improved EFS with second-line lisocabtagene maraleucel vs standard of care salvage immunochemotherapy followed by autologous stem cell transplantation in relapsed or...

An interim analysis of the phase...

08/23/2022

Oncology

News

Tisagenlecleucel Associated With Improved Response Rates, Reduced Risk of Death vs Historical Treatments for DLBCL

06/14/2022

John Otrompke

Third-line or later treatment with tisagenlecleucel is associated with significantly higher response rates and significantly lower risk of death compared with historical control treatments for patients with relapsed/refractory DLBCL.

Third-line or later treatment...

06/14/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology